Are you living with major depressive disorder (MDD)? Are you experiencing persistent sadness, hopelessness, irritability, restlessness, guilt or worthlessness? Indago is
collaborating with Axsome Therapeutics on a research study to assess the safety of solriamfetol in adults with depression (SOL-MDD-301 or PARADIGM).
What is the PARADIGM depression research study?#
The PARADIGM study is a clinical research study currently being conducted at select centers in the US. The study is for people aged 18 to 65 who are currently experiencing the symptoms of depression*. The PARADIGM study is to assess the safety of solriamfetol for the treatment of major depressive disorder in adults
*Other criteria also apply.
What are the symptoms of depression?#
Adults living with depression may experience some or all of the following symptoms, most of the day, nearly every day, for at least two weeks:1
– Persistent sadness
– Feelings of hopelessness
– Feelings of irritability or restlessness
– Feelings of guilt or worthlessness
– Loss of interest or pleasure in hobbies and activities
– Decreased energy or fatigue
– Difficulty concentrating, remembering, or making decisions
– Difficulty sleeping or oversleeping
– Changes in appetite or unplanned weight changes
Not everyone who is depressed experiences the symptoms listed above and this is not an exhaustive list
Who Can Participate?#
People who are aged 18 to 65 in the U.S. who are currently experiencing symptoms of depression may be eligible. Other criteria also apply.
Why Participate?#
If you’re living with depression, the PARADIGM study may be right for you. If you are eligible to participate:
- You may receive the investigational medication.
- You may receive study-related care and study evaluations at no cost.
- You may also receive compensation for your time and travel.
- You may have the opportunity to help advance potential new treatments for people with depression*.
*Solriamfetol is an investigational oral medication being studied for major depressive disorder.
Call us for more information: 786-772-0510
1. Institute of Health Metrics and Evaluation. Global Health Data Exchange (GHDx). http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-permalink/d780dffbe8a381b25e1416884959e88b (Accessed 1 May 2021).
